Description:
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating
the safety and efficacy of trilaciclib versus placebo administered prior to gemcitabine and
carboplatin in patients receiving first- or second-line treatment for locally advanced
unresectable/metastatic TNBC.
Title
- Brief Title: Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
- Official Title: A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
Clinical Trial IDs
- ORG STUDY ID:
G1T28-208
- SECONDARY ID:
2020-004930-39
- NCT ID:
NCT04799249
Conditions
- TNBC - Triple-Negative Breast Cancer
- Breast Cancer
Interventions
Drug | Synonyms | Arms |
---|
Trilaciclib | G1T28, COSELA | Trilaciclib + gemcitabine + carboplatin |
Placebo | 0.9% normal saline, 5 % Dextrose in water (D5W) | Placebo + gemcitabine + carboplatin |
Gemcitabine | | Placebo + gemcitabine + carboplatin |
Carboplatin | | Placebo + gemcitabine + carboplatin |
Purpose
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating
the safety and efficacy of trilaciclib versus placebo administered prior to gemcitabine and
carboplatin in patients receiving first- or second-line treatment for locally advanced
unresectable/metastatic TNBC.
Detailed Description
This study will have two separate cohorts (Cohort 1 and Cohort 2). Both cohorts will follow
the same general study conduct/design with similar primary and key secondary endpoints and
identical treatment arms.
- Cohort 1 will evaluate patients receiving first-line therapy, regardless of programmed
death-ligand 1 (PD-L1) status, who are programmed cell death protein 1 (PD-1)/PD-L1
inhibitor therapy naïve.
- Cohort 2 will evaluate PD-L1 positive patients receiving second-line therapy following
prior PD-1/PD-L1 inhibitor therapy in the locally advanced unresectable/metastatic
setting.
Trial Arms
Name | Type | Description | Interventions |
---|
Trilaciclib + gemcitabine + carboplatin | Experimental | Trilaciclib (240mg/m2) + gemcitabine (1000 mg/m2) and carboplatin (AUC 2) | - Trilaciclib
- Gemcitabine
- Carboplatin
|
Placebo + gemcitabine + carboplatin | Placebo Comparator | The subjects in the placebo arm will follow the same schedule as the trilaciclib arm, but will receive placebo instead of trilaciclib. | - Placebo
- Gemcitabine
- Carboplatin
|
Eligibility Criteria
Inclusion Criteria:
1. Age >/= 18 years of age with evaluable locally advanced unresectable or metastatic
TNBC.
2. Documentation of triple negative breast cancer (estrogen and progesterone receptor <1%
and HER2-negative)
3. Prior systemic therapies (Cohort 1 only):
1. No prior systemic therapy in the locally advanced unresectable/metastatic setting
including chemotherapy, targeted therapy, immunotherapy, or investigational
agents.
2. Prior PD-1/PD-L1 inhibitor treatment is not permitted in any setting, including
in the neoadjuvant setting.
3. Time between completion of last treatment with curative intent and first
metastatic recurrence must be ≥ 6 months.
4. Prior systemic therapies (Cohort 2 only):
1. Documentation of PD-L1 positive status
2. Treated with a PD-1/PD-L1 inhibitor for a minimum duration of 4 months in the
locally advanced unresectable/metastatic setting and as the most recent therapy.
5. Radiation therapy for metastatic disease is permitted. There is no required minimum
washout period for radiation therapy. Patients should be recovered from the effects of
radiation.
6. Archival tumor tissue must be available or a fresh biopsy must be obtained, unless
approved by the Medical Monitor.
7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
8. Adequate organ function as demonstrated by normal laboratory values
Exclusion Criteria:
1. Prior treatment with gemcitabine in any setting.
2. Prior treatment with carboplatin in the locally advanced unresectable/metastatic
setting.
Prior carboplatin in the (neo)adjuvant/curative setting is permitted as long as it was
completed ≥ 6 months prior to the first metastatic recurrence.
3. Presence of central nervous system (CNS) metastases and/or leptomeningeal disease
requiring immediate treatment with radiation therapy or steroids.
4. Receipt of any cytotoxic chemotherapy within 14 days prior to the first dose of study
drugs.
5. QTcF interval >480 msec at Screening (confirmed in triplicate). For patients with
ventricular pacemakers, QTcF >500 msec.
6. Known hypersensitivity to carboplatin or other platinum-containing compounds, or
mannitol
7. Pregnant or lactating women
8. Prior hematopoietic stem cell or bone marrow transplantation
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Effect on Overall Survival (OS) |
Time Frame: | Cohort 1:From date of randomization up to 39 months |
Safety Issue: | |
Description: | (Cohort 1):To evaluate the effect of trilaciclib on overall survival (OS) compared with placebo in patients receiving first-line gemcitabine and carboplatin. |
Secondary Outcome Measures
Measure: | Quality of life/Effects On Chemotherapy-Induced Fatigue |
Time Frame: | Cycle 1 Day 1 (each cycle is 21 days) up to 14 months |
Safety Issue: | |
Description: | To assess the effect of trilaciclib on patients' quality of life as measured by time to first confirmed deterioration of fatigue compared with placebo in patients receiving gemcitabine and carboplatin |
Measure: | Myeloprotective Effects |
Time Frame: | Cycle 1 Day 1 (each cycle is 21 days) up to 14 months |
Safety Issue: | |
Description: | Occurrence of cytopenias, febrile neutropenia, hospitalization due to chemotherapy-induced myelosuppression, RBC and platelet transfusions, growth factor administration, and dose reductions and delays |
Measure: | Progression Free Survival |
Time Frame: | From date of randomization up to 14 months) |
Safety Issue: | |
Description: | To evaluate the effect of trilaciclib on progression-free survival (PFS) compared with placebo in patients receiving gemcitabine and carboplatin. |
Details
Phase: | Phase 3 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | G1 Therapeutics, Inc. |
Trial Keywords
- breast cancer
- gemcitabine
- carboplatin
- solid tumors
- breast
- chemotherapy
- TNBC
- trilaciclib
- cyclin-dependent kinase 4/6 inhibitor
- CDK 4/6 Inhibitor
- triple-negative breast cancer
- metastatic
- chemotherapy-induced fatigue
- HER2-negative
- immunotherapy
- immune checkpoint inhibitor therapy
- chemotherapy-induced myelosuppression
- myeloprotection
- myeloprotective
- PD-1/PD-L1 inhibitor therapy
- advanced
- stage 4
- preserve
- PRESERVE 2
Last Updated
August 17, 2021